FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387562887> ?p ?o ?g. }

• W4387562887 abstract "We aimed to evaluate the activity of selinexor, an oral selective inhibitor of nuclear export, in patients with recurrent or metastatic salivary gland tumors (SGT).GEMS-001 is an open-label Phase 2 study for patients with recurrent or metastatic SGT with two parts. In Part 1 of the protocol, patients had tumor samples profiled with targeted next generation sequencing as well as immunohistochemistry for androgen receptor, HER-2 and ALK. For Part 2, patients with no targeted therapies available were eligible to receive selinexor 60 mg given twice weekly every 28 days. The primary endpoint was objective response rate. Secondary endpoints included progression-free survival (PFS) and prevalence of druggable alterations across SGT.One hundred patients were enrolled in GEMS-001 and underwent genomic and immunohistochemistry profiling. A total of 21 patients who lacked available matched therapies were treated with selinexor. SGT subtypes (WHO classification) included adenoid cystic carcinoma (n = 10), salivary duct carcinoma (n = 3), acinic cell carcinoma (n = 2), myoepithelial carcinoma (n = 2), carcinoma ex pleomorphic adenoma (n = 2) and other (n = 2). Of 18 evaluable patients, stable disease (SD) was observed in 17 patients (94%) (SD ≥6 months in 7 patients (39%)). However, no objective responses were observed. The median PFS was 4.9 months (95% confidence interval, 3.4-10). The most common treatment-related Grade 1-2 adverse events were nausea [17 patients (81%)], fatigue [16 patients (76%)], and dysgeusia [12 patients (57%)]. Most common treatment-related Grade 3-4 adverse events were hyponatremia [3 patients (14%)], neutrophil count decrease [3 patients (14%)] and cataracts [2 patients (10%)]. No treatment-related deaths were observed.Although tumor reduction was observed across participants, single agent selinexor anti-tumor activity was limited." @default.
• W4387562887 created "2023-10-13" @default.
• W4387562887 creator A5000204204 @default.
• W4387562887 creator A5013524271 @default.
• W4387562887 creator A5013892733 @default.
• W4387562887 creator A5017037813 @default.
• W4387562887 creator A5021603375 @default.
• W4387562887 creator A5022267545 @default.
• W4387562887 creator A5028677586 @default.
• W4387562887 creator A5050622730 @default.
• W4387562887 creator A5061503927 @default.
• W4387562887 creator A5066673450 @default.
• W4387562887 creator A5067900139 @default.
• W4387562887 creator A5073690674 @default.
• W4387562887 creator A5085722332 @default.
• W4387562887 creator A5088186975 @default.
• W4387562887 date "2023-10-11" @default.
• W4387562887 modified "2023-10-13" @default.
• W4387562887 title "Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the <scp>GEMS</scp>‐001 clinical trial" @default.
• W4387562887 cites W1442402616 @default.
• W4387562887 cites W1560364460 @default.
• W4387562887 cites W1987494556 @default.
• W4387562887 cites W2086417538 @default.
• W4387562887 cites W2087945589 @default.
• W4387562887 cites W2147128400 @default.
• W4387562887 cites W2187721367 @default.
• W4387562887 cites W2290633618 @default.
• W4387562887 cites W2291746651 @default.
• W4387562887 cites W2543337034 @default.
• W4387562887 cites W2588106078 @default.
• W4387562887 cites W2600928401 @default.
• W4387562887 cites W2788138717 @default.
• W4387562887 cites W2800882200 @default.
• W4387562887 cites W2805668464 @default.
• W4387562887 cites W2884635903 @default.
• W4387562887 cites W2887920894 @default.
• W4387562887 cites W2969931905 @default.
• W4387562887 cites W2997604945 @default.
• W4387562887 cites W3029783040 @default.
• W4387562887 cites W3037697670 @default.
• W4387562887 cites W3041891326 @default.
• W4387562887 cites W3093641368 @default.
• W4387562887 cites W3106123507 @default.
• W4387562887 cites W3168051285 @default.
• W4387562887 cites W3193695517 @default.
• W4387562887 cites W4293074148 @default.
• W4387562887 cites W4296502312 @default.
• W4387562887 doi "https://doi.org/10.1002/cam4.6589" @default.
• W4387562887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37818869" @default.
• W4387562887 hasPublicationYear "2023" @default.
• W4387562887 type Work @default.
• W4387562887 citedByCount "0" @default.
• W4387562887 crossrefType "journal-article" @default.
• W4387562887 hasAuthorship W4387562887A5000204204 @default.
• W4387562887 hasAuthorship W4387562887A5013524271 @default.
• W4387562887 hasAuthorship W4387562887A5013892733 @default.
• W4387562887 hasAuthorship W4387562887A5017037813 @default.
• W4387562887 hasAuthorship W4387562887A5021603375 @default.
• W4387562887 hasAuthorship W4387562887A5022267545 @default.
• W4387562887 hasAuthorship W4387562887A5028677586 @default.
• W4387562887 hasAuthorship W4387562887A5050622730 @default.
• W4387562887 hasAuthorship W4387562887A5061503927 @default.
• W4387562887 hasAuthorship W4387562887A5066673450 @default.
• W4387562887 hasAuthorship W4387562887A5067900139 @default.
• W4387562887 hasAuthorship W4387562887A5073690674 @default.
• W4387562887 hasAuthorship W4387562887A5085722332 @default.
• W4387562887 hasAuthorship W4387562887A5088186975 @default.
• W4387562887 hasBestOaLocation W43875628871 @default.
• W4387562887 hasConcept C126322002 @default.
• W4387562887 hasConcept C143998085 @default.
• W4387562887 hasConcept C197934379 @default.
• W4387562887 hasConcept C203092338 @default.
• W4387562887 hasConcept C2777054765 @default.
• W4387562887 hasConcept C2777546739 @default.
• W4387562887 hasConcept C2778937882 @default.
• W4387562887 hasConcept C2779231225 @default.
• W4387562887 hasConcept C2780329156 @default.
• W4387562887 hasConcept C2780859518 @default.
• W4387562887 hasConcept C2780885620 @default.
• W4387562887 hasConcept C2781066530 @default.
• W4387562887 hasConcept C2781437628 @default.
• W4387562887 hasConcept C535046627 @default.
• W4387562887 hasConcept C71924100 @default.
• W4387562887 hasConcept C90924648 @default.
• W4387562887 hasConceptScore W4387562887C126322002 @default.
• W4387562887 hasConceptScore W4387562887C143998085 @default.
• W4387562887 hasConceptScore W4387562887C197934379 @default.
• W4387562887 hasConceptScore W4387562887C203092338 @default.
• W4387562887 hasConceptScore W4387562887C2777054765 @default.
• W4387562887 hasConceptScore W4387562887C2777546739 @default.
• W4387562887 hasConceptScore W4387562887C2778937882 @default.
• W4387562887 hasConceptScore W4387562887C2779231225 @default.
• W4387562887 hasConceptScore W4387562887C2780329156 @default.
• W4387562887 hasConceptScore W4387562887C2780859518 @default.
• W4387562887 hasConceptScore W4387562887C2780885620 @default.
• W4387562887 hasConceptScore W4387562887C2781066530 @default.
• W4387562887 hasConceptScore W4387562887C2781437628 @default.
• W4387562887 hasConceptScore W4387562887C535046627 @default.
• W4387562887 hasConceptScore W4387562887C71924100 @default.
• W4387562887 hasConceptScore W4387562887C90924648 @default.

• next